Experienced founders with an entrepreneurial mindset

After graduating from HEC in 1989 and the financial track of INSEAD in 1996, he immediately joined Deutsche Bank’s Healthcare Group in Frankfurt and then Baltimore and New York.

While on assignment as an expatriate for Deutsche Bank, he managed to pioneer and supercharge the development of the merging Deutsche Bank cross-border franchise alongside the transatlantic trajectory, providing a maximizing exposure to the globalization of healthcare and a quantum-leap in both Client and knowledge databases, since he was bringing a totally different jurisdictional and cultural background to his US Clients.

He then took over the M&A Group at Boehringer Ingelheim in 2003, a career inflection point with regards to his life- science knowledge, because of the intensive interaction with scientists and biologists, epidemiologists… Corporate M&A is a different discipline than investment banking M&A, which enables him to decipher how M&A is perceived within large Corporates and to focus on further fundamental aspects such as remaining and restructuring costs and socio-political repercussions such as pension, employment continuation guarantees and phased social plans.

He also refined his sensitivity to operational aspects of all ancillary agreements to be entered concurrently with the principal Sale and Purchase Agreement and gained first-ranking exposure to strategic and business development/portfolio management aspects, such as globalization of footprint, bio-generics threats, leverage of manufacturing and sales-force capacities.

He then went on to lead Cowen’s European Healthcare Investment Banking in London from 2007, rebuilding the European franchise, and developing its US and Global Client network, reengaging them at the Top Level into an intense M&A-dialogue with Top Clients, as the driving force originating numerous cross-border M&A transactions especially in the vaccine, drug delivery technology, CRO, dermatology and dermatology and oncology biotech.

From 2008 to 2010, he was Senior M&A Adviser at Bryan, Garnier in Paris, where he led-managed the execution of a Capital Markets and M&A transactions in the ophthalmology sector (IPO of Novagali in 2010), oncology biotech and immuno-therapeutics ( Share Capital Increase of Transgene in 2010), diagnostics in oncology (Exonhit’s IPO in 2009) and in CNS (IPO of Integragen in 2010 ) and M&A transactions (divestiture of Institut Mérieux’s Vaccine Business Shantha Biotechnics in 2009) as well as acquisition by Biomérieux of AES-Chemunex in 2010.

During his 13 years’ tenure at Michel Dyens, he elevated his expertise in M&A and partnerships transactions in the Specialty Pharma, Vaccines, Diagnostics, Medtech and especially Medical Aesthetics spaces, Physician-Dispensed Skincare and Healthcare services. He also focused on situations involving the therapy and patient-centric management of age-related chronic, degenerative diseases and the area of regenerative and reconstructive medicine as well as medical spas offering facial and body remodeling services (Transactions).

Jean-Yves has been a keynote speaker on megatrends, prospectives and M&A valuations at the World Economic Tribunes of IMCAS for 10 years and was recently invited to intervene at other prestigious and influential events such as SOFCEP in France, the Aesthetic Innovation Summit in the US or online at the Global Virtual Aesthetic Summit.

At ENSCM, he became knowledgeable on every aspect of Pharma R&D. First he joined the French Centre for National Research CNRS) in Montpellier as a synthetic chemist in early-stage academic research before moving to the USA at GlaxoSmithKline in North Carolina within the group Chemical Biology providing public-private partnership in collaboration with Duke University, Durham, North Carolina. As a medicinal chemist, he designed and developed small molecules kinases inhibitors for oncology and epigenetics (HDACS inhibitors). Besides, he took an active part in projects with GSK’s skincare subsidiary Stiefel to develop new forms of drug delivery systems.

He then joined Sanofi in Paris in the CSR department Access to Medicine, specializing in drug procurement for developing countries, validating IMPD (Investigational Medicinal Product Dossier) for infectious diseases especially malaria and sleeping disease.

He then obtained an advanced master in strategy and international management at ESSEC Business School in collaboration with the MBA program of Thunderbird Global School of Management in Phoenix, Arizona, USA, a world reference for global management.

In 2014, he had the opportunity to join the Healthcare team of Michel Dyens & Co. and quickly became an expert in dermatology and medical aesthetics with several key landmark cross-border transactions in these sectors. He took an active part in congresses on the topic of better ageing (IMCAS, AMWC, FRED Dermatology) which he found captivating. Indeed, Florian has a passion for sports and healthy lifestyle,practicing many sports and competing in numerous swimming, HYROX® and Crossfit® events and seeking for an expert knowledge on biomechanics, physical training, nutrition, and protocols. He holds a Crossfit® level 1 training degree.

His Vision with WINDOME BANKING PARTNERS:

To help people that shares his values with regards to prevention, better aging and healthy lifestyle, obtaining the financial support they need to catalyse their research projects and commercial expansion. The goal is to expand the reach of traditional Mid-Market M&A advisory by having a clear added value in strategic decisions, digging deeper into sciences and market intelligence in healthcare supported by a scientific advisory board and working in close relationships with KOLs, and by creating a team with specialized skills and double degrees. He also wanted to create a truly decentralized company with no geographic restrictions, a unique expertise in cross-border deal making supported by a multilingual agile team. He sees WINDOME collaborators as business and financial athletes committed to further pushing their limits to disrupt the status quo.